Access BIO - Home Page.

Preclinical pharmacology/toxicology programs to support Phase I clinical trials
Expedited regulatory mechanisms
Regulatory strategies to gain competitive advantage
Rapid and uninterrupted clinical development
Human subjects protection
Strategies for combination products
Leveraging discovery research
Meeting with the FDA

Access BIO is a consulting group which specializes in assisting in the development of drug, biologic and medical device products.

Our experience as policy makers at the FDA, in particular The Center for Biologics Evaluation and Research (CBER), as well as our broad consulting practice allow us the ability to offer our partners advice on the best regulatory strategies and in the development of rational scientific preclinical and clinical approaches to meet the scrutiny of the FDA and other regulatory authorities. This experience extends to many aspects of biomedical research and product development including vaccines, cellular therapy, gene therapy, blood products, biotechnology products and Institutional Review Board (IRB) participation. Our experience also includes tissue and plant-derived products.

Let us help you in developing the best approach and well-defined protocols in the clinical and animal studies to speed FDA product approval.